Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.

Among 40 evaluable patients with metastatic renal cell cancer treated by high-dose interferon alpha-2a in combination with vinblastine, the authors have observed a 42.5% response rate. The 8 months' median duration of remissions is relatively short but some patients experience very long remissions, lasting many months after discontinuation of therapy.

[Treatment of metastatic renal adenocarcinomas with combined recombinant alpha-2a interferon and vinblastine].

The results of treatment of metastatic renal cell carcinoma have so far been very poor. Many phase II studies have shown that interferon alpha therapy is active in a significant proportion of patients (approximately 10 to 15% complete and partial remission). In the hope of improving these results we have conducted a phase I-II study of the combination of interferon alpha-2a and vinblastine in 21 patients with metastatic renal cell cancer.

[Invasive cancer of the prostate. Reconstruction of the lower urinary tract by prostatic resection and ureteral reimplantation into the bladder vault].

Some prostatic cancers (T4) spread out along the ureters to the kidneys. Patients, usually arrive with terminal renal failure and bladder retention and have often fast-advancing cancer with massive nodes invading. T.

Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients.

30 patients with advanced prostatic carcinomas received sequential polychemotherapy with association of vincristine (or VM 26), cyclophosphamide and 5-fluorouracil. In addition, 13 of these 30 patients received a dose of adriamycin during the first day of treatment, which did not change the results. This treatment was well tolerated and gave a good relief of bone pains.